1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) is a synthetic lung surfactant used to treat infant respiratory distress syndrome. Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant.
- Mechanism
- Curator reviewed
Palmitoyloleoyl-phosphatidylglycerol reduces interfacial tension at the air/water interfaces in the alveoli. This prevents the tension from pulling the alveolar membranes inwards which would collapse them and lead to respiratory distress.
- Primary indication
- Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin which was indicated for the prevention of respiratory distress syndrome in premature infants.Curator reviewed
- Formula / weight
- C40H77O10P · 749.02 g/mol (avg)
- First approval
- United States, 2013
- Also known as
- Palmitoyloleoyl-phosphatidylglycerol · PG(16:0/18:1) · POPG
Resolves to
PAZGBAOHGQRCBP-DDDNOICHSA-NSMILESCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCCWhat you can answer from here — as of August 30, 2026
Which drugs share a target with 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)), and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account